Searched for
SYNGENE EARNINGS
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Smallcap winners! Wockhardt, Tata Tech, CAMS, other stocks rally up to 11% despite overall market weaknessSmallcap stocks outperformed on Tuesday despite weak broader markets, with Wockhardt, Tata Tech and CAMS gaining up to 11% on strong Q4 ear...
- Ahead of Market: 10 things that will decide stock market action on MondayIndian stock markets experienced sharp cuts on Thursday, with Nifty and Sensex declining due to rising oil prices and a falling rupee. Sell...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Syngene Q3 Results: Net profit rose 18% YoY to Rs 131 croreSyngene reported 18% YoY growth in Q3FY25 net profit. Revenue rose 11% YoY. EBITDA margin improved to 31.4%. Company expects single-digit r...
- Syngene Q1 Results: Net profit drops 19% to Rs 76 croreSyngene International, the contract research and manufacturing services arm of Biocon, reported 19% year-on-year (YoY) drop in net profit t...
- Syngene Q4 Results: Net profit rises 6% to Rs 189 crore, revenue drops 8%The earnings before interest, tax, depreciation and ammortisation dropped 1% YoY to Rs. 333 crore in Q4FY24. The EBITDA margin rose 300 bas...
- Syngene International Q3 Results: Net profit rises 2% YoY to Rs 112 crore, company revises revenue guidanceThe rise in Q3 profit of Syngene International was led by dedicated centres and development and manufacturing services, even as discovery s...
- Syngene Q2 Results: Net profit jumps 14% to Rs 117 croreNet profit before an exceptional item rose 20% YoY to 122 crore. The exceptional item pertains to transaction costs relating to the acquisi...
- Syngene reports Rs 102 crore net profit in Q2FY23The company reported net profit of Rs 102 crore during Q2FY23, compared to Rs 67 crore during the corresponding quarter of the previous yea...
- Syngene International skids 4% as Q4 PAT declines 8% YoYOn a standalone basis, the company’s quarterly net profit stood at Rs 147 crore in March 2022, down 8.41 per cent from Rs 160.50 crore in M...
- Jefferies maintains 'buy' on Syngene International, target price of Rs 350Shares of Syngene International ended up 1.7% at Rs 298.65 on Wednesday.
- Syngene makes strong debut on the bourses, jumps 24%Syngene International, a research arm of biotech major Biocon, made a strong debut on the bourses on Tuesday.
- Syngene International makes stellar debut, ends day up 24% over issue priceIt hit an intraday high of Rs 318.20 over its issue price, before settling the day at Rs 310.40, up 24.16 per cent on the BSE.
- Is it time to book profits on Biocon counter post Syngene listing?Biocon has gained nearly 9 per cent in the past six months, compared to a 2 per cent fall in the BSE benchmark Sensex.
- Syngene's valuations are fair, investors need to invest in its growth story: Kiran Mazumdar-ShawIn an interview with ET Now, Kiran Mazumdar-Shaw, CMD, Biocon, talks about the Syngene IPO and the growth prospects involved.
- Top brokers recommend 'subscribe' to Syngene International IPO; here's whyLong-term investors should 'subscribe' to Syngene IPO which opens for subscription today, various brokerages said in a report.
- Syngene valuation justified by high growth prospectsPremium valuation seems justified given the good track record in performance, high quality of earnings and growth potential.
- Biocon to sell up to 25% in Syngene via IPOBiocon will launch an IPO for its fully-owned contract research subsidiary Syngene this financial year.
Load More
